subchapter_subject: "ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS"
part_code: "520"
part_subject: "ORAL DOSAGE FORM NEW ANIMAL DRUGS"
subpart_code: "B"
subpart_subject: "Specific Administrative Rulings and Decisions"
section_number: "520.370"
section_subject: "Cefpodoxime tablets."
cfr_reference: "21 CFR 520.370"
title_name: "Title 21"
title_subject: "Food and Drugs"
parts_covered: "Parts 500 to 599"
revised_date: "Revised as of April 1, 2019"
publication_date: "As of April 1, 2019"
contains_description: "Containing a codification of documents of general applicability and future effect"
publication_info: "Published by the Office of the Federal Register National Archives and Records Administration as a Special Edition of the Federal Register"
---
(a)Specifications. (1) Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime.
(2)Each chewable tablet contains cefpodoxime proxetil equivalent to 100 or 200 mg cefpodoxime.
(b)Sponsors. See sponsors in § 510.600(c) of this chapter for uses as follows:
(1)No. 026637 for use of product in paragraph (a)(1) of this section as in paragraph (c) of this section.
(2)No. 054771 for use of products in paragraph (a) of this section as in paragraph (c) of this section.
(c)Conditions of use in dogs—(1) Amount. 5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.
(2)Indications for use. For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, S. aureus, Streptococcus canis (group G, beta-hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
(3)Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.